Copyright Reports & Markets. All rights reserved.

Global Emergency Hemostatic Agent Market Research Report 2021

Request for Sample of this report
Buy now

1 Emergency Hemostatic Agent Market Overview

  • 1.1 Product Overview and Scope of Emergency Hemostatic Agent
  • 1.2 Emergency Hemostatic Agent Segment by Type
    • 1.2.1 Global Emergency Hemostatic Agent Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Gelation Sponge
    • 1.2.3 Oxidized Regenerated Cellulose Based Hemostats
    • 1.2.4 Others
  • 1.3 Emergency Hemostatic Agent Segment by Application
    • 1.3.1 Emergency Hemostatic Agent Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospitals
    • 1.3.3 Surgical Centers
    • 1.3.4 Clnics
    • 1.3.5 Others
  • 1.4 Global Emergency Hemostatic Agent Market Size Estimates and Forecasts
    • 1.4.1 Global Emergency Hemostatic Agent Revenue 2016-2027
    • 1.4.2 Global Emergency Hemostatic Agent Sales 2016-2027
    • 1.4.3 Emergency Hemostatic Agent Market Size by Region: 2016 Versus 2021 Versus 2027

2 Emergency Hemostatic Agent Market Competition by Manufacturers

  • 2.1 Global Emergency Hemostatic Agent Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Emergency Hemostatic Agent Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Emergency Hemostatic Agent Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Emergency Hemostatic Agent Manufacturing Sites, Area Served, Product Type
  • 2.5 Emergency Hemostatic Agent Market Competitive Situation and Trends
    • 2.5.1 Emergency Hemostatic Agent Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Emergency Hemostatic Agent Players Market Share by Revenue
    • 2.5.3 Global Emergency Hemostatic Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Emergency Hemostatic Agent Retrospective Market Scenario by Region

  • 3.1 Global Emergency Hemostatic Agent Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Emergency Hemostatic Agent Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Emergency Hemostatic Agent Market Facts & Figures by Country
    • 3.3.1 North America Emergency Hemostatic Agent Sales by Country
    • 3.3.2 North America Emergency Hemostatic Agent Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Emergency Hemostatic Agent Market Facts & Figures by Country
    • 3.4.1 Europe Emergency Hemostatic Agent Sales by Country
    • 3.4.2 Europe Emergency Hemostatic Agent Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Emergency Hemostatic Agent Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Emergency Hemostatic Agent Sales by Region
    • 3.5.2 Asia Pacific Emergency Hemostatic Agent Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Emergency Hemostatic Agent Market Facts & Figures by Country
    • 3.6.1 Latin America Emergency Hemostatic Agent Sales by Country
    • 3.6.2 Latin America Emergency Hemostatic Agent Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Emergency Hemostatic Agent Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Emergency Hemostatic Agent Sales by Country
    • 3.7.2 Middle East and Africa Emergency Hemostatic Agent Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Emergency Hemostatic Agent Historic Market Analysis by Type

  • 4.1 Global Emergency Hemostatic Agent Sales Market Share by Type (2016-2021)
  • 4.2 Global Emergency Hemostatic Agent Revenue Market Share by Type (2016-2021)
  • 4.3 Global Emergency Hemostatic Agent Price by Type (2016-2021)

5 Global Emergency Hemostatic Agent Historic Market Analysis by Application

  • 5.1 Global Emergency Hemostatic Agent Sales Market Share by Application (2016-2021)
  • 5.2 Global Emergency Hemostatic Agent Revenue Market Share by Application (2016-2021)
  • 5.3 Global Emergency Hemostatic Agent Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Ethicon
    • 6.1.1 Ethicon Corporation Information
    • 6.1.2 Ethicon Description and Business Overview
    • 6.1.3 Ethicon Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Ethicon Product Portfolio
    • 6.1.5 Ethicon Recent Developments/Updates
  • 6.2 Pfizer
    • 6.2.1 Pfizer Corporation Information
    • 6.2.2 Pfizer Description and Business Overview
    • 6.2.3 Pfizer Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Pfizer Product Portfolio
    • 6.2.5 Pfizer Recent Developments/Updates
  • 6.3 Baxter International
    • 6.3.1 Baxter International Corporation Information
    • 6.3.2 Baxter International Description and Business Overview
    • 6.3.3 Baxter International Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Baxter International Product Portfolio
    • 6.3.5 Baxter International Recent Developments/Updates
  • 6.4 C. R. Bard
    • 6.4.1 C. R. Bard Corporation Information
    • 6.4.2 C. R. Bard Description and Business Overview
    • 6.4.3 C. R. Bard Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 C. R. Bard Product Portfolio
    • 6.4.5 C. R. Bard Recent Developments/Updates
  • 6.5 The Medicines Company
    • 6.5.1 The Medicines Company Corporation Information
    • 6.5.2 The Medicines Company Description and Business Overview
    • 6.5.3 The Medicines Company Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 The Medicines Company Product Portfolio
    • 6.5.5 The Medicines Company Recent Developments/Updates
  • 6.6 Anika Therapeutics
    • 6.6.1 Anika Therapeutics Corporation Information
    • 6.6.2 Anika Therapeutics Description and Business Overview
    • 6.6.3 Anika Therapeutics Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Anika Therapeutics Product Portfolio
    • 6.6.5 Anika Therapeutics Recent Developments/Updates
  • 6.7 Advanced Medical Solutions
    • 6.6.1 Advanced Medical Solutions Corporation Information
    • 6.6.2 Advanced Medical Solutions Description and Business Overview
    • 6.6.3 Advanced Medical Solutions Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Advanced Medical Solutions Product Portfolio
    • 6.7.5 Advanced Medical Solutions Recent Developments/Updates
  • 6.8 Integra LifeSciences
    • 6.8.1 Integra LifeSciences Corporation Information
    • 6.8.2 Integra LifeSciences Description and Business Overview
    • 6.8.3 Integra LifeSciences Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Integra LifeSciences Product Portfolio
    • 6.8.5 Integra LifeSciences Recent Developments/Updates
  • 6.9 B Braun Melsungen
    • 6.9.1 B Braun Melsungen Corporation Information
    • 6.9.2 B Braun Melsungen Description and Business Overview
    • 6.9.3 B Braun Melsungen Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 B Braun Melsungen Product Portfolio
    • 6.9.5 B Braun Melsungen Recent Developments/Updates
  • 6.10 Gelita Medical
    • 6.10.1 Gelita Medical Corporation Information
    • 6.10.2 Gelita Medical Description and Business Overview
    • 6.10.3 Gelita Medical Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Gelita Medical Product Portfolio
    • 6.10.5 Gelita Medical Recent Developments/Updates
  • 6.11 Equimedical
    • 6.11.1 Equimedical Corporation Information
    • 6.11.2 Equimedical Emergency Hemostatic Agent Description and Business Overview
    • 6.11.3 Equimedical Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Equimedical Product Portfolio
    • 6.11.5 Equimedical Recent Developments/Updates
  • 6.12 Vascular Solutions
    • 6.12.1 Vascular Solutions Corporation Information
    • 6.12.2 Vascular Solutions Emergency Hemostatic Agent Description and Business Overview
    • 6.12.3 Vascular Solutions Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Vascular Solutions Product Portfolio
    • 6.12.5 Vascular Solutions Recent Developments/Updates
  • 6.13 Marine Polymer Technologies
    • 6.13.1 Marine Polymer Technologies Corporation Information
    • 6.13.2 Marine Polymer Technologies Emergency Hemostatic Agent Description and Business Overview
    • 6.13.3 Marine Polymer Technologies Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Marine Polymer Technologies Product Portfolio
    • 6.13.5 Marine Polymer Technologies Recent Developments/Updates
  • 6.14 Z-Medica
    • 6.14.1 Z-Medica Corporation Information
    • 6.14.2 Z-Medica Emergency Hemostatic Agent Description and Business Overview
    • 6.14.3 Z-Medica Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Z-Medica Product Portfolio
    • 6.14.5 Z-Medica Recent Developments/Updates
  • 6.15 CryoLife
    • 6.15.1 CryoLife Corporation Information
    • 6.15.2 CryoLife Emergency Hemostatic Agent Description and Business Overview
    • 6.15.3 CryoLife Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 CryoLife Product Portfolio
    • 6.15.5 CryoLife Recent Developments/Updates
  • 6.16 BioCer Entwicklungs
    • 6.16.1 BioCer Entwicklungs Corporation Information
    • 6.16.2 BioCer Entwicklungs Emergency Hemostatic Agent Description and Business Overview
    • 6.16.3 BioCer Entwicklungs Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.16.4 BioCer Entwicklungs Product Portfolio
    • 6.16.5 BioCer Entwicklungs Recent Developments/Updates
  • 6.17 Biom’Up SAS
    • 6.17.1 Biom’Up SAS Corporation Information
    • 6.17.2 Biom’Up SAS Emergency Hemostatic Agent Description and Business Overview
    • 6.17.3 Biom’Up SAS Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2016-2021)
    • 6.17.4 Biom’Up SAS Product Portfolio
    • 6.17.5 Biom’Up SAS Recent Developments/Updates

7 Emergency Hemostatic Agent Manufacturing Cost Analysis

  • 7.1 Emergency Hemostatic Agent Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Emergency Hemostatic Agent
  • 7.4 Emergency Hemostatic Agent Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Emergency Hemostatic Agent Distributors List
  • 8.3 Emergency Hemostatic Agent Customers

9 Emergency Hemostatic Agent Market Dynamics

  • 9.1 Emergency Hemostatic Agent Industry Trends
  • 9.2 Emergency Hemostatic Agent Growth Drivers
  • 9.3 Emergency Hemostatic Agent Market Challenges
  • 9.4 Emergency Hemostatic Agent Market Restraints

10 Global Market Forecast

  • 10.1 Emergency Hemostatic Agent Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Emergency Hemostatic Agent by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Emergency Hemostatic Agent by Type (2022-2027)
  • 10.2 Emergency Hemostatic Agent Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Emergency Hemostatic Agent by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Emergency Hemostatic Agent by Application (2022-2027)
  • 10.3 Emergency Hemostatic Agent Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Emergency Hemostatic Agent by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Emergency Hemostatic Agent by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Gelation Sponge
    Oxidized Regenerated Cellulose Based Hemostats
    Others

    Segment by Application
    Hospitals
    Surgical Centers
    Clnics
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Ethicon
    Pfizer
    Baxter International
    C. R. Bard
    The Medicines Company
    Anika Therapeutics
    Advanced Medical Solutions
    Integra LifeSciences
    B Braun Melsungen
    Gelita Medical
    Equimedical
    Vascular Solutions
    Marine Polymer Technologies
    Z-Medica
    CryoLife
    BioCer Entwicklungs
    Biom’Up SAS

    Buy now